1. Scrip
  2. >>Therapy Areas

Bluebird Bio Sings Cheerily Of Its "Biggest ASH Ever"

 
• By Emily Hayes

Company highlights LentiGlobin sickle cell and beta thalassemia data updates in investor call about the upcoming ASH meeting, which will feature 11 presentations across its clinical and preclinical programs.

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells

bluebird bio Inc. says that data updates at the upcoming American Society of Hematology meeting in December show that new manufacturing changes for its gene therapy LentiGlobin are working well in sickle cell disease and beta thalassemia studies.

Abstracts for the ASH annual meeting, which will be held Dec. 9 to 12 in Atlanta, were posted on Nov....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?